Company Description
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases.
It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve.
The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta.
Anteris Technologies Global Corp. is based in Toowong, Australia.
| Country | Australia |
| Founded | 1999 |
| IPO Date | Dec 13, 2024 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 136 |
| CEO | Wayne Paterson |
Contact Details
Address: Toowong Tower, Level 3, Suite 302 Toowong, QLD 4066 Australia | |
| Phone | 61 7 3152 3200 |
| Website | anteristech.com |
Stock Details
| Ticker Symbol | AVR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 2011514 |
| ISIN Number | US03675P1021 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Wayne Geoffrey Paterson | Vice Chairman and Chief Executive Officer |
| David St. Denis | President and Director |
| Matthew McDonnell | Chief Financial Officer |
| Dr. Chris Meduri M.D., M.P.H. | Chief Medical Officer and Member of Medical Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 5, 2026 | SCHEDULE 13G/A | Filing |
| Jan 29, 2026 | SCHEDULE 13D | Filing |
| Jan 23, 2026 | 424B3 | Prospectus |
| Jan 22, 2026 | 8-K | Current Report |
| Jan 22, 2026 | 8-K | Current Report |
| Jan 22, 2026 | 424B5 | Filing |
| Jan 21, 2026 | SCHEDULE 13G/A | Filing |
| Jan 21, 2026 | FWP | Free Writing Prospectus |
| Jan 20, 2026 | FWP | Free Writing Prospectus |
| Jan 20, 2026 | 424B5 | Filing |